Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
BMJ Open Gastroenterology|December 8, 2025
Comparative evaluation of a hybrid machine learning-human adjudication paradigm for endoscopic scoring in ulcerative colitisKlaus T Gottlieb, Chakib Battioui, Yeli Wang, et al.Digital Biomarkers|July 5, 2023
Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body DementiaChakib Battioui, Albert Man, Melissa Pugh, et al.Diagnostics (Basel, Switzerland)|July 13, 2024
External Validation of the Machine Learning-Based Thermographic Indices for Rheumatoid Arthritis: A Prospective Longitudinal StudyIsabel Morales-Ivorra, Delia Taverner, Oriol Codina, et al.American Heart Journal|July 27, 2019
Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug developmentDavid H Manner, Chakib Battioui, Stefan Hantel, et al.Journal of Parkinson'S Disease|June 13, 2022
Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body DementiaJian Wang, Chakib Battioui, Andrew McCarthy, et al.Diabetes Care|May 20, 2011
Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemiaItamar Raz, Antonio Ceriello, Peter W Wilson, et al.Parkinsonism & Related Disorders|March 11, 2023
Wrist-worn sensor-based measurements for drug effect detection with small samples in people with Lewy Body DementiaChen Chen, Nathan R Kowahl, Erin Rainaldi, et al.Neurology|February 20, 2025
ARIA Insights from the Donanemab Trials (P1-9.001)Steven Greenberg, Chakib Battioui, Ming Lu, et al.Hepatology Communications|May 16, 2018
Coding variants in <i>PNPLA3</i> and <i>TM6SF2</i> are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonistCristina B Guzman, Suman Duvvuru, Anthony Akkari, et al.Alzheimer'S & Dementia (New York, N. Y.)|March 10, 2026
Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's diseasePaul Ardayfio, Garrett R Mullins, Rashna Khanna, et al.Pageof 2